For Healthcare Professionals

Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options

clipboard-pencil

About the study

A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Male and female aged at least 18 years, or male and female aged 16 years or 17 years and who weigh at least 40 kg whom have given informed consent
  2. Ability and willingness to comply with the protocol.
  3. Able to take oral medication
  4. Female must be non-lactating and at no risk of pregnancy
  5. Male with female partners of childbearing potential must either abstain from sexual intercourse or use a highly effective means of contraception
  6. Patients with invasive fungal disease
  7. Patients who have limited alternative treatment options

EXCLUSION CRITERIA

  1. Women who are pregnant or breastfeeding.
  2. Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug.
  3. Patients with chronic aspergillosis, aspergilloma or allergic bronchopulmonary aspergillosis.
  4. HIV infection but not currently receiving antiretroviral therapy.
  5. Patients with a medical condition that may jeopardize adherence to the protocol or may cause unacceptable additional risk to the patient
  6. Previously enrolled patients or patients enrolled in any clinical trial within the last 30 days
  7. Patients receiving treatment limited to supportive care due to predicted short survival time.
  8. Prohibited concomitant medications.
  9. Any exclusion criteria required by local regulatory authorities.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 43 664 3582281Email iconEmail Study Center

Study’s details


Contition

Invasive Fungal Infections

Age

16+

Phase

Phase 2

Participants needed

200

Est. Completion Date

Apr 2023

Treatment type

Interventional


Sponsor

F2G Biotech GmbH

ClinicalTrials.gov identifier

NCT03583164

Study number

F9013180032

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.